For privately held companies, Isomorphic’s raise is the second-largest in biotech history, surpassed only by Altos Labs’ $3 billion debut in 2022.

For privately held companies, Isomorphic’s raise is the second-largest in biotech history, surpassed only by Altos Labs’ $3 billion debut in 2022.

Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it might bring to the clinic.

The funding round brings on board new investors including Temasek and the UK Sovereign AI Fund.

Alphabet's Isomorphic Labs has raised more than $2bn in funds to accelerate AI-powered drug discovery and tech expansion.